SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2023
SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced its preliminary and unaudited revenue for fourth quarter and full year 2023.
Related news for (SIBN)
- SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance
- SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance
- SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024
- SI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024
- SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application